|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2006-8-16
|
|
pubmed:abstractText |
Elevated plasma levels of plasminogen activator inhibitor-1 (PAI-1) are observed in patients with obesity, hypertension and diabetes, and several observations suggest that PAI-1 mediates diabetic vascular complications. Although increased intrarenal expression of PAI-1 is also a feature of diabetic nephropathy, evidence that PAI-1 plays a primary pathogenetic role in the renal pathology is lacking.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1660-2129
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2006 S. Karger AG, Basel.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
104
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
e23-34
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:16735799-Animals,
pubmed-meshheading:16735799-Blood Glucose,
pubmed-meshheading:16735799-Cholesterol,
pubmed-meshheading:16735799-Diabetes Mellitus, Experimental,
pubmed-meshheading:16735799-Diabetic Nephropathies,
pubmed-meshheading:16735799-Extracellular Matrix,
pubmed-meshheading:16735799-Female,
pubmed-meshheading:16735799-Kidney,
pubmed-meshheading:16735799-Male,
pubmed-meshheading:16735799-Mice,
pubmed-meshheading:16735799-Mice, Inbred Strains,
pubmed-meshheading:16735799-Plasminogen Activator Inhibitor 1,
pubmed-meshheading:16735799-Urokinase-Type Plasminogen Activator
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice.
|
|
pubmed:affiliation |
Children's Hospital and Regional Medical Center, Department of Pediatrics, University of Washington, Seattle, Wash, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
